GlassScriptPhysician profile
Jennifer J Pickett
NPI 1265682009
$2,907.86
in general payments reported to CMS, 2019-2025
29 companies · $503 in 2025
The $503 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.77 · 2022: $17.82 · 2023: $266 · 2024: $2,102 · 2025: $503.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.28 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.15 | 2024-2025 | |
| Lilly USA, LLC | $332.84 | 2023-2025 | Emgality, Reyvow, Kisunla |
| Pfizer INC. | $298.46 | 2024-2025 | |
| Biogen, INC. | $204.51 | 2024-2025 | Vumerity, Tysabri, Leqembi |
| Argenx US, INC. | $204.05 | 2024-2025 | Vyvgart Hytrulo |
| Sk Life Science, INC. | $129.95 | 2023-2024 | Xcopri |
| Eisai INC. | $127.61 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $112.51 | 2024-2025 | Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $106.89 | 2023-2024 | |
| Csl Behring | $104.85 | 2023-2024 | Hizentra |
| Harmony Biosciences LLC | $91.92 | 2023-2024 | Wakix |
| Averitas Pharma INC. | $77.55 | 2023-2024 | Qutenza |
| Jazz Pharmaceuticals INC. | $76.91 | 2024 | |
| Inspire Medical Systems, INC. | $61.41 | 2024 | Inspire |
| Alexion Pharmaceuticals, INC. | $54.98 | 2024 | Ultomiris |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $54.27 | 2025 | Jornay Pm |
| Corium, LLC | $54.21 | 2025 | Azstarys |
| Acorda Therapeutics, INC | $46.40 | 2023-2024 | Inbrija |
| Intuitive Surgical, INC. | $35.61 | 2023 | |
| Idorsia Pharmaceuticals US INC | $35.58 | 2024 | Quviviq |
| Cranial Technologies, INC | $32.59 | 2025 | Doc Band |
| Lundbeck LLC | $31.02 | 2025 | Vyepti |
| Sanofi Pasteur INC. | $28.62 | 2025 | |
| Pharming Healthcare, INC. | $26.54 | 2025 | Ruconest |
| Amgen INC. | $25.74 | 2024 | Uplizna |
| Grifols USA, LLC | $21.61 | 2024 | Gamunex-C |
| Neurocrine Biosciences, INC. | $21.49 | 2025 | |
| Genentech USA, INC. | $18.77 | 2021 | |
| Medtronic, INC. | $17.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Pickett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.